HMN 2025: What are the Guidelines for nonoccupational postexposure prophylaxis for HIV

Updated suggestions for antiretroviral nonoccupational postexposure prophylaxis (nPEP) for HIV have been published within the May 8 problem of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Mary R. Tanner, M.D., from the CDC in Atlanta, and colleagues up to date the 2016 nPEP pointers and concerns to be used within the United States, together with concerns for testing and nPEP regimens for individuals uncovered who’ve acquired long-acting injectable antiretroviral brokers up to now.

The authors notice that for many adults and adolescents, the popular regimens are bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir plus (tenofovir alafenamide or tenofovir disoproxil fumarate) plus (emtricitabine or lamivudine). The regimens will be tailor-made to particular medical circumstances. For individuals prescribed nPEP, medical follow-up also needs to be tailor-made to the medical state of affairs; really helpful follow-up features a distant or in-person go to with a medical supplier at 24 hours and medical follow-up at 4 to 6 and 12 weeks after publicity for laboratory testing. Persons initiating nPEP needs to be knowledgeable that preexposure prophylaxis (PrEP) can scale back their threat for buying HIV within the case of repeat or persevering with publicity after the nPEP course. PrEP choices needs to be provided to these with ongoing indications, and an nPEP-to-PrEP transition plan needs to be created.

“Communication and schooling methods are wanted to extend each supplier and group consciousness of nPEP,” the authors write.